One To Watch

Collegium Pharmaceutical

A Nasdaq-listed specialty pharmaceutical company focused on the development and commercialization of medicines for pain management and neuropsychiatric conditions. Collegium Pharmaceutical has built a commercial portfolio centered on responsible pain therapies and ADHD treatment.

Company Overview

Collegium Pharmaceutical is a commercial-stage biopharmaceutical company developing and marketing therapies for serious medical conditions, with a primary focus on chronic pain and a growing presence in neuropsychiatry.

The company’s strategy is centered on building a diversified portfolio of differentiated medicines, combining internal development with acquisitions and licensing. Its business model is largely commercial rather than discovery-driven, with revenue generated from marketed products.

Collegium has positioned itself as a developer of responsible pain therapies, focusing on opioid formulations designed to reduce misuse while maintaining efficacy. The addition of ADHD therapies has broadened its commercial base beyond pain management.

Headquarters and Global Presence

Collegium is headquartered in Stoughton, Massachusetts, United States, and operates primarily in the U.S. with a commercial infrastructure focused on product distribution and lifecycle management.

Founding and History

Founded in 2002, the company initially focused on abuse-deterrent opioid formulations and completed its Nasdaq IPO in 2015.

Over time, Collegium expanded its portfolio through acquisitions, including Ironshore Therapeutics and BioDelivery Sciences International. These transactions shifted the company from a single-product biotech into a diversified commercial pharmaceutical business.

Therapy Areas and Focus

Collegium focuses on a limited number of therapeutic areas.

chronic and severe pain management
neuropsychiatry, particularly attention deficit hyperactivity disorder

The company prioritizes indications where formulation and delivery innovation can provide differentiation.

Technology Platforms and Modalities

The company’s differentiation is based on formulation technologies rather than novel biological targets.

DETERx microsphere technology for extended-release delivery
abuse-deterrent opioid formulations
modified-release oral drug delivery systems

These approaches are designed to improve safety, control drug release and reduce the potential for misuse.

Key Portfolio and Programs

Xtampza ER is an extended-release oxycodone formulation and the company’s flagship product for chronic pain.

Nucynta, available in immediate- and extended-release forms, is a tapentadol-based analgesic used for moderate to severe pain.

Belbuca is a buprenorphine buccal film for chronic pain, offering an alternative opioid delivery approach.

Jornay PM is an extended-release methylphenidate product for ADHD and represents a key growth driver outside the pain portfolio.

Symproic is an oral therapy for opioid-induced constipation, complementing the company’s pain franchise.

Key Personnel

Vikram Karnani, President and Chief Executive Officer

Strategic Partnerships

Collegium’s strategy relies on acquisitions, licensing and commercial partnerships rather than internal early-stage research.

Key elements include prior acquisitions of Ironshore Therapeutics and BioDelivery Sciences International, as well as ongoing relationships supporting distribution and lifecycle management of marketed products.

FAQ Section

The central strategic issue is the sustainability of a portfolio heavily weighted toward opioid-based therapies. The company must balance commercial growth with regulatory scrutiny and long-term shifts in pain management practices.

The company’s core products are opioid analgesics, which carry risks of misuse. Collegium’s strategy emphasizes abuse-deterrent formulations to mitigate these risks while maintaining therapeutic benefit.

Its differentiation lies in formulation technologies such as DETERx, which enable extended release and reduce the potential for manipulation and misuse.

Jornay PM provides diversification into ADHD and reduces reliance on the pain portfolio, supporting long-term revenue stability.

While the company has multiple marketed products, the majority of revenue is still derived from pain therapies, with ADHD representing the primary area of diversification.

Collegium is a commercial-stage pharmaceutical company focused on marketed products, lifecycle management and portfolio expansion rather than early-stage R&D.

Key issues include regulatory pressure on opioid products, competition from generics, growth of the ADHD franchise and the company’s ability to expand its portfolio through acquisitions.

Want to Update your Company's Profile?